Search
Coauthors
Curt Essenburg Center for Cancer and Cell Biology, Van Andel Research Institute, USA
1 protocol

Elizabeth Tovar Center for Cancer and Cell Biology, Van Andel Research Institute, USA
1 protocol

Carrie Graveel
  • Center for Cancer and Cell Biology, Van Andel Research Institute, USA
  • 1 Author merit

Education

Ph.D in Cellular and Molecular Biology, University of Wisconsin-Madison, 2002

Current Position

Senior Research Scientist, Van Andel Research Institute, Michigan, USA

Publications (sicne  2005)

  1. Linklater, E. S., Tovar, E. A., Essenburg, C. J., Turner, L., Madaj, Z., Winn, M. E., Melnik, M. K., Korkaya, H., Maroun, C. R., Christensen, J. G., Steensma, M. R., Boerner, J. L. and Graveel, C. R. (2016). Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget. [Epub ahead of print]
  2. Gilani, R. A., Phadke, S., Bao, L. W., Lachacz, E. J., Dziubinski, M. L., Brandvold, K. R., Steffey, M. E., Kwarcinski, F. E., Graveel, C. R., Kidwell, K. M., Merajver, S. D. and Soellner, M. B. (2016). UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer. Clin Cancer Res 22(20): 5087-5096.
  3. Sameni, M., Tovar, E. A., Essenburg, C. J., Chalasani, A., Linklater, E. S., Borgman, A., Cherba, D. M., Anbalagan, A., Winn, M. E., Graveel, C. R. and Sloane, B. F. (2016). Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models. Clin Cancer Res 22(4): 923-934.
  4. Lane, B. R., Bissonnette, J., Waldherr, T., Ritz-Holland, D., Chesla, D., Cottingham, S. L., Alberta, S., Liu, C., Thompson, A. B., Graveel, C., MacKeigan, J. P., Noyes, S. L., Smith, J., Lakhani, N., Steensma, M. R. and Spectrum Health Tumor Sequencing Advisory, B. (2015). Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board. J Mol Diagn 17(6): 695-704.
  5. Graveel, C. R., Calderone, H. M., Westerhuis, J. J., Winn, M. E. and Sempere, L. F. (2015). Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press) 7: 59-79.
  6. MacKenzie, T. A., Schwartz, G. N., Calderone, H. M., Graveel, C. R., Winn, M. E., Hostetter, G., Wells, W. A. and Sempere, L. F. (2014). Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. Am J Pathol 184(12): 3217-3225.
  7. Popkie, A., Kakarala, M. and Graveel, C. (2014). Genetic and environmental influences on stem cells and breast cancer. Current Pathobiology Reports 2(1): 27-32.
  8. Paulson, A. K., Linklater, E. S., Berghuis, B. D., App, C. A., Oostendorp, L. D., Paulson, J. E., Pettinga, J. E., Melnik, M. K., Vande Woude, G. F. and Graveel, C. R. (2013). MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res 11(9): 1112-1121.
  9. Graveel, C. R., Tolbert, D. and Vande Woude, G. F. (2013). MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 5(7).
  10. Valkenburg, K. C., Graveel, C. R., Zylstra-Diegel, C. R., Zhong, Z. and Williams, B. O. (2011). Wnt/beta-catenin Signaling in Normal and Cancer Stem Cells. Cancers (Basel) 3(2): 2050-2079.
  11. Graveel, C. R., DeGroot, J. D., Sigler, R. E. and Vande Woude, G. F. (2010). Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One 5(10): e13586.
  12. Graveel, C. R., DeGroot, J. D., Su, Y., Koeman, J., Dykema, K., Leung, S., Snider, J., Davies, S. R., Swiatek, P. J., Cottingham, S., Watson, M. A., Ellis, M. J., Sigler, R. E., Furge, K. A. and Vande Woude, G. F. (2009). Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A 106(31): 12909-12914.
  13. Graveel, C. R., London, C. A. and Vande Woude, G. F. (2005). A mouse model of activating Met mutations. Cell Cycle 4(4): 518-520.
1 Protocol published
In vivo Efficacy Studies in Cell Line and Patient-derived Xenograft Mouse Models
Authors:  Elizabeth A. Tovar, Curt J. Essenburg and Carrie Graveel, date: 01/05/2017, view: 2535, Q&A: 0
In vivo xenograft models derived from human cancer cells have been a gold standard for evaluating the genetic drivers of cancer and are valuable preclinical models for evaluating the efficacy of cancer therapeutics. Recently, ...